Buy Clomid (Clomiphene) Prices | Cheap Generic Clomid Online | Canadian Med Pharmacy

You can purchase Clomid Online and Order Cheap Clomid Online Save up to 80% off Clomid prices !!!
Buying Clomid Without a Prescription from Canadian Med Pharmacy

Infertility is not a diesease. Every one in five couples struggle with infertility at any given time. Infertiltiy has increased as a problem over the last 30 years. But thanks to Clomiphene therapy, a growing number of once-infertile couples are now proud parents.

Being termed Infertile doesn’t mean that you will never become pregnant. Nowadays, you have a reasonable chance of overcoming.

When nature needs help, Clomiphene Citrate ( commercially known as Clomid and Serophene) is a good first choice drug. Clomiphene works by changing the hormone balance of the body This causes ovulation to occur and prepares the body for pregnancy.

And now you can stop paying ridiculous prices for your Clomid .you can order Clomid at drastically reduced prices, legally without a prescription needed. Purchases can be made directly from your computer within minutes. Meds arrive in your mailbox in 2-3 weeks weeks or sooner via First Class Airmail.

CLOMID®
SEROPHENE®

Manufacturer : Aventis Pharmaceuticals Inc. [ Clomid ]
Serono Laboratories,Inc. [ Serophene ]

Chemical Name : Clomiphene

Indications

Treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning Clomid therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see Ovarian Hyperstimulation Syndrome under Warnings), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology.
Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of Clomid should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about 6 cycles (including 3 ovulatory cycles). (See Dosage & Administration and Precautions.)
Clomid is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described as follows (see Contraindications):
Patients who are not pregnant.
Patients without ovarian cysts. Clomid should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the 1st and each subsequent course of Clomid treatment.
Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present.
Patients with normal liver function.
In addition, patients selected for Clomid therapy should be evaluated in regard to the following:
Estrogen Levels: Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy.
Primary Pituitary or Ovarian Failure: Clomid therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure.
Endometriosis and Endometrial Carcinoma: The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to Clomid therapy in this population.
Other Impediments to Pregnancy: Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia and male factor infertility.
Uterine Fibroids: Caution should be exercised when using Clomid in patients with uterine fibroids due to the potential for further enlargement of the fibroids.
There are no adequate or well-controlled studies that demonstrate the effectiveness of Clomid in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of Clomid is not known.
Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (ie, Clomid in conjunction with other ovulation-inducing drugs). Similarly, there is no standard Clomid regimen for ovulation induction in in vitro fertilization programs to produce ova for fertilization and re-introduction. Therefore, Clomid is not recommended for these uses.

Dosage

General Considerations: The work-up and treatment of candidates for Clomid therapy should be supervised by physicians experienced in management of gynecologic or endocrine disorders. Patients should be chosen for therapy with Clomid only after careful diagnostic evaluation (see Indications). The plan of therapy should be outlined in advance. Impediments to achieving the goal of therapy must be excluded or adequately treated before beginning Clomid. The therapeutic objective should be balanced with potential risks and discussed with the patient and others involved in the achievement of pregnancy.
Ovulation most often occurs from 5-10 days after a course of Clomid. Coitus should be timed to coincide with the expected time of ovulation. Appropriate tests to determine ovulation may be useful during this time.
Recommended Dosage: Treatment of the selected patient should begin with a low dose, 50 mg daily (1 tab) for 5 days. The dose should be increased only in those patients who do not ovulate in response to cyclic 50 mg Clomid. A low dosage or duration of treatment course is particularly recommended if unusual sensitivity to pituitary gonadotropin is suspected, eg in patients with polycystic ovary syndrome (see Ovarian Hyperstimulation Syndrome under Warnings).
The patient should be evaluated carefully to exclude pregnancy, ovarian enlargement or ovarian cyst formation between each treatment cycle.
If progestin-induced bleeding is planned, or if spontaneous uterine bleeding occurs prior to therapy, the regimen of 50 mg daily for 5 days should be started on or about the 5th day of the cycle. Therapy may be started at any time in the patient who has had no recent uterine bleeding. When ovulation occurs at this dosage, there is no advantage to increasing the dose in subsequent cycles of treatment.
If ovulation does not appear to occur after the 1st course of therapy, a 2nd course of 100 mg daily (two 50-mg tabs given as a single-daily dose) for 5 days should be given. This course may be started as early as 30 days after the previous one after precautions are taken to exclude the presence of pregnancy. Increasing the dosage or duration of therapy beyond 100 mg/day for 5 days is not recommended.
The majority of patients who are going to ovulate will do so after the 1st course of therapy. If ovulation does not occur after 3 courses of therapy, further treatment with Clomid is not recommended and the patient should be re-evaluated. If 3 ovulatory responses occur, but pregnancy has not been achieved, further treatment is not recommended. If menses do not occur after an ovulatory response, the patient should be re-evaluated. Long-term cyclic therapy is not recommended beyond a total of about 6 cycles (see Precautions).

This page is not endorsed or affiliated with the Aventis, Serono Company.
All trademarks and registered trademarks are of their respective companies.